heart attack; platelets or blood blots in legs broke apart in legs , traveled up to the heart; blood clots in legs broke apart in legs and traveled up to the heart; problem with leg; This spontaneous case was reported by a consumer and describes the occurrence of MYOCARDIAL INFARCTION (heart attack), THROMBOSIS (platelets or blood blots in legs broke apart in legs , traveled up to the heart) and EMBOLISM (blood clots in legs broke apart in legs and traveled up to the heart) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020F21A and 053C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Surgery. Concurrent medical conditions included Diabetes and Hypertension.   On 09-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYOCARDIAL INFARCTION (heart attack) (seriousness criteria hospitalization and medically significant), THROMBOSIS (platelets or blood blots in legs broke apart in legs , traveled up to the heart) (seriousness criteria hospitalization and medically significant), EMBOLISM (blood clots in legs broke apart in legs and traveled up to the heart) (seriousness criteria hospitalization and medically significant) and LIMB DISCOMFORT (problem with leg). At the time of the report, MYOCARDIAL INFARCTION (heart attack), THROMBOSIS (platelets or blood blots in legs broke apart in legs , traveled up to the heart) and EMBOLISM (blood clots in legs broke apart in legs and traveled up to the heart) outcome was unknown and LIMB DISCOMFORT (problem with leg) had not resolved.            Concomitant products were not provided. Consumer stated after his 1st dose he did not feel as bad. Consumer added he felt worse with second dose. Consumer stated that went on till November. Consumer stated his platelets or blood blots in legs broke apart in legs, traveled up to the heart, and clogged up 10 arteries in heart.Following that event he had a heart attack.Consumer stated he had to get a surgery done at the hospital. For his first surgery they used balloon pump. Then the doctors were going to use stent, but were not able to. They took a vein out of his leg and put in the heart.  Company comment: This spontaneous case concerns a 56-year-old male patient, with medical history of diabetes and hypertension, who experienced the serious (medically significant, hospitalization) events of MYOCARDIAL INFARCTION, THROMBOSIS and THROMBOEMBOLISM. The events occurred on an unknown date after receiving a second dose of mRNA-1273. According to source document narrative, patient experienced blood clots in legs that traveled up to the heart and clogged up to 10 arteries in the heart, causing a heart attack. He was treated with surgery. No further information regarding hospitalization or details on received treatment was provided. Patient's history of diabetes and hypertension remains as a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.   This case was linked to MOD-2022-460354 (Patient Link).   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a 56-year-old male patient, with medical history of diabetes and hypertension, who experienced the serious (medically significant, hospitalization) events of MYOCARDIAL INFARCTION, THROMBOSIS and THROMBOEMBOLISM. The events occurred on an unknown date after receiving a second dose of mRNA-1273. According to source document narrative, patient experienced blood clots in legs that traveled up to the heart and clogged up to 10 arteries in the heart, causing a heart attack. He was treated with surgery. No further information regarding hospitalization or details on received treatment was provided. Patient's history of diabetes and hypertension remains as a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.